Table 1 Primary genome-wide significant associations for anti-drug antibody phenotypes.

From: Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Phenotype

Variant type

N or N case/N control

Variant ID

chr:pos (hg19)

Nearest gene(s)

Imputation@

A1/A2^

A1 freq

Beta (SE) S.D. or OR (95%CI)

p

ADA positive

AA variant#

2841/5933

AA_DRB1_120_32657518_N

6:32549539

DRB1

MHC

A/P*

0.13

0.66 (0.57–0.71)

1.68E−17

AA variant#

 

AA_DQB1_75_32740612

6:32632633

DQB1

MHC

L/V

0.25

1.25 (1.16–1.34)

4.84E−09

SNP

 

rs3093664

6:31544641

TNF

MHC

G/A

0.08

1.40 (1.25–1.58)

2.69E−08

ADA max titer

SNP

2841

rs7756741

6:32583197

DQA1/DRB1

MHC

A/T

0.33

0.19 (0.03)

1.68E−12

SNP

 

rs3763313

6:32376470

BTNL2

MHC

A/C

0.25

0.17 (0.03)

3.98E−08

ADA max titer top 10%

AA variant#

286/2555

AA_DQB1_71_32740624_KD

6:32632633

DQB1

MHC

P/A*

0.25

1.72(1.43:2.06)

5.24E−09

NAb max titer

SNP

312

rs78928382

18:370039

COLEC12

HRC

G/A

0.06

−0.85 (0.15)

1.87e−08

SNP

 

rs111663071

6:120683067

intergenic

HRC

A/G

0.06

0.65 (0.12)

2.35E−08

  1. Index SNPs determined by clumping with LD R2 = 0.1. #Notation is AA_gene_residue_nucleotide b.36_encoded amino acid(s)21 @Imputation using the genome-wide HRC panel (HRC) or the MHC panel (MHC). ^A1 = coded (i.e. effect) allele/A2 = non-coded allele, indicated as alternative single letter amino acid code for AA variants or alternative nucleotide for SNPs. *AA in variant ID present (P) or absent (A). Covariates were age, sex, study, PCs 1–5.
Back to article page